Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 512

1.

Undifferentiated Wharton's Jelly Mesenchymal Stem Cell Transplantation Induces Insulin-Producing Cell Differentiation and Suppression of T-Cell-Mediated Autoimmunity in Nonobese Diabetic Mice.

Tsai PJ, Wang HS, Lin GJ, Chou SC, Chu TH, Chuan WT, Lu YJ, Weng ZC, Su CH, Hsieh PS, Sytwu HK, Lin CH, Chen TH, Shyu JF.

Cell Transplant. 2015;24(8):1555-70. doi: 10.3727/096368914X683016. Epub 2014 Jul 15.

PMID:
25198179
2.

Effect and mechanisms of human Wharton's jelly-derived mesenchymal stem cells on type 1 diabetes in NOD model.

Hu J, Wang Y, Wang F, Wang L, Yu X, Sun R, Wang Z, Wang L, Gao H, Fu Z, Zhao W, Yan S.

Endocrine. 2015 Feb;48(1):124-34. doi: 10.1007/s12020-014-0219-9. Epub 2014 Mar 4.

PMID:
24590294
3.

Exendin-4 enhances the differentiation of Wharton's jelly mesenchymal stem cells into insulin-producing cells through activation of various β-cell markers.

Kassem DH, Kamal MM, El-Kholy Ael-L, El-Mesallamy HO.

Stem Cell Res Ther. 2016 Aug 11;7(1):108. doi: 10.1186/s13287-016-0374-4.

4.

Human Wharton's Jelly-Derived Stem Cells Display Immunomodulatory Properties and Transiently Improve Rat Experimental Autoimmune Encephalomyelitis.

Donders R, Vanheusden M, Bogie JF, Ravanidis S, Thewissen K, Stinissen P, Gyselaers W, Hendriks JJ, Hellings N.

Cell Transplant. 2015;24(10):2077-98. doi: 10.3727/096368914X685104. Epub 2014 Oct 10.

PMID:
25310756
5.

Association of expression levels of pluripotency/stem cell markers with the differentiation outcome of Wharton's jelly mesenchymal stem cells into insulin producing cells.

Kassem DH, Kamal MM, El-Kholy Ael-L, El-Mesallamy HO.

Biochimie. 2016 Aug;127:187-95. doi: 10.1016/j.biochi.2016.05.019. Epub 2016 Jun 3.

PMID:
27265786
6.

Obestatin can potentially differentiate Wharton's jelly mesenchymal stem cells into insulin-producing cells.

El-Asfar RK, Kamal MM, Abd El-Razek RS, El-Demerdash E, El-Mesallamy HO.

Cell Tissue Res. 2018 Apr;372(1):91-98. doi: 10.1007/s00441-017-2725-6. Epub 2017 Nov 20.

PMID:
29159483
7.

A comparison of Wharton's jelly and cord blood as a source of mesenchymal stem cells for diabetes cell therapy.

El-Demerdash RF, Hammad LN, Kamal MM, El Mesallamy HO.

Regen Med. 2015;10(7):841-55. doi: 10.2217/rme.15.49. Epub 2015 Nov 6.

PMID:
26541176
8.

Overexpression of apelin in Wharton' jelly mesenchymal stem cell reverses insulin resistance and promotes pancreatic β cell proliferation in type 2 diabetic rats.

Gao LR, Zhang NK, Zhang Y, Chen Y, Wang L, Zhu Y, Tang HH.

Stem Cell Res Ther. 2018 Dec 7;9(1):339. doi: 10.1186/s13287-018-1084-x. Erratum in: Stem Cell Res Ther. 2019 Jan 8;10(1):6.

10.

Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus.

Hu J, Yu X, Wang Z, Wang F, Wang L, Gao H, Chen Y, Zhao W, Jia Z, Yan S, Wang Y.

Endocr J. 2013;60(3):347-57. Epub 2012 Nov 16.

11.

Effect of combined therapy of human Wharton's jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats.

Hu J, Wang F, Sun R, Wang Z, Yu X, Wang L, Gao H, Zhao W, Yan S, Wang Y.

Endocrine. 2014 Mar;45(2):279-87. doi: 10.1007/s12020-013-9984-0. Epub 2013 May 18.

PMID:
23686639
12.

Treatment With Human Wharton's Jelly-Derived Mesenchymal Stem Cells Attenuates Sepsis-Induced Kidney Injury, Liver Injury, and Endothelial Dysfunction.

Cóndor JM, Rodrigues CE, Sousa Moreira Rd, Canale D, Volpini RA, Shimizu MH, Camara NO, Noronha Ide L, Andrade L.

Stem Cells Transl Med. 2016 Aug;5(8):1048-57. doi: 10.5966/sctm.2015-0138. Epub 2016 Jun 8.

13.

Intravenous vs intraperitoneal transplantation of umbilical cord mesenchymal stem cells from Wharton's jelly in the treatment of streptozotocin-induced diabetic rats.

El-Hossary N, Hassanein H, El-Ghareeb AW, Issa H.

Diabetes Res Clin Pract. 2016 Nov;121:102-111. doi: 10.1016/j.diabres.2016.09.008. Epub 2016 Sep 21.

PMID:
27693839
14.

Transplantation of insulin-producing cells differentiated from human periosteum-derived progenitor cells ameliorate hyperglycemia in diabetic mice.

Dao LT, Park EY, Lim SM, Choi YS, Jung HS, Jun HS.

Transplantation. 2014 Nov 27;98(10):1040-7. doi: 10.1097/TP.0000000000000388.

PMID:
25208321
15.

Transplantation of insulin-producing cells derived from umbilical cord stromal mesenchymal stem cells to treat NOD mice.

Wang HS, Shyu JF, Shen WS, Hsu HC, Chi TC, Chen CP, Huang SW, Shyr YM, Tang KT, Chen TH.

Cell Transplant. 2011;20(3):455-66. doi: 10.3727/096368910X522270. Epub 2010 Aug 18.

PMID:
20719086
16.

Infusion with Human Bone Marrow-derived Mesenchymal Stem Cells Improves β-cell Function in Patients and Non-obese Mice with Severe Diabetes.

Li L, Hui H, Jia X, Zhang J, Liu Y, Xu Q, Zhu D.

Sci Rep. 2016 Dec 1;6:37894. doi: 10.1038/srep37894.

17.
18.

Comparisons of Differentiation Potential in Human Mesenchymal Stem Cells from Wharton's Jelly, Bone Marrow, and Pancreatic Tissues.

Kao SY, Shyu JF, Wang HS, Lin CH, Su CH, Chen TH, Weng ZC, Tsai PJ.

Stem Cells Int. 2015;2015:306158. doi: 10.1155/2015/306158. Epub 2015 Jul 29.

19.

Human chorionic-plate-derived mesenchymal stem cells and Wharton's jelly-derived mesenchymal stem cells: a comparative analysis of their potential as placenta-derived stem cells.

Kim MJ, Shin KS, Jeon JH, Lee DR, Shim SH, Kim JK, Cha DH, Yoon TK, Kim GJ.

Cell Tissue Res. 2011 Oct;346(1):53-64. doi: 10.1007/s00441-011-1249-8. Epub 2011 Oct 11.

PMID:
21987220
20.

Hydrogen peroxide preconditioning enhances the therapeutic efficacy of Wharton's Jelly mesenchymal stem cells after myocardial infarction.

Zhang J, Chen GH, Wang YW, Zhao J, Duan HF, Liao LM, Zhang XZ, Chen YD, Chen H.

Chin Med J (Engl). 2012 Oct;125(19):3472-8.

PMID:
23044308

Supplemental Content

Support Center